Cyteir Therapeutics Inc (CYT)
$3.01
$-0.01
(-0.33%)
As on 12-Apr-2024 09:30EDT
Market cap
$109 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-30 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.9
-
Face value
--
-
Shares outstanding
35,998,100
5 Years Aggregate
CFO
$-140.45 Mln
EBITDA
$-125.76 Mln
Net Profit
$-154.68 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cyteir Therapeutics Inc (CYT)
| -1.0 | -0.7 | -2.9 | 63.6 | -- | -- | -- |
|
BSE Sensex*
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Cyteir Therapeutics Inc (CYT)
| 84.2 | -85.5 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Cyteir Therapeutics Inc (CYT)
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II... clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts. Read more
-
Independent Investor & Independent Chairman of the Board
Mr. Joseph S. Zakrzewski
-
Independent Investor & Independent Chairman of the Board
Mr. Joseph S. Zakrzewski
-
Headquarters
Lexington, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cyteir Therapeutics Inc (CYT)
What is the current share price of Cyteir Therapeutics Inc (CYT) Today?
The share price of Cyteir Therapeutics Inc (CYT) is $3.01 (NASDAQ) as of 12-Apr-2024 09:30 EDT. Cyteir Therapeutics Inc (CYT) has given a return of 63.59% in the last 1 years.
What is the current PB & PE ratio of Cyteir Therapeutics Inc (CYT)?
Since, TTM earnings of Cyteir Therapeutics Inc (CYT) is negative, P/E ratio is not available.
The P/B ratio of Cyteir Therapeutics Inc (CYT) is 0.87 times as on 12-Apr-2024, a 84 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-1.33 |
0.40 |
2021 |
-9.59 |
2.13 |
2020 |
-- |
-- |
2019 |
-- |
-- |
2022 |
-1.33 |
0.40 |
What is the 52 Week High and Low of Cyteir Therapeutics Inc (CYT)?
The 52-week high and low of Cyteir Therapeutics Inc (CYT) are Rs -- and Rs -- as of 11-Sep-2026.
What is the market cap of Cyteir Therapeutics Inc (CYT)?
Cyteir Therapeutics Inc (CYT) has a market capitalisation of $ 109 Mln as on 12-Apr-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Cyteir Therapeutics Inc (CYT)?
Before investing in Cyteir Therapeutics Inc (CYT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.